As June begins, a lot of news: COVID-19 vaccine guidance continues to change, and BIO is dedicating its focus entirely to human health. (929 words, 4 minutes, 38 seconds) BIO to focus on human health ...

Washington, DC, May 28, 2025 – The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work of its Agriculture and ...

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...

A busy April is flying by. Today, we look at the executive order on drug pricing, the threat of pharmaceutical tariffs, a CDC meeting on immunization practices, and BIO’s appearances at many ...

Today, we have details on the National Security Commission on Emerging Biotechnology’s new report—and why tariffs still threaten biotech, including pharma and ag. (816 words, 4 minutes, 4 seconds) ...

WASHINGTON, DC, April 8, 2025 – Today, the National Security Commission on Emerging Biotechnology (NSCEB), a bipartisan legislative commission established by Congress, issued its much-anticipated ...

John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary ...

WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical ...

WASHINGTON D.C. – Today, the Biotechnology Innovation Organization (BIO), in partnership with Kearney, a global management consulting firm, released a first-of-its-kind report that assesses the ...

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

WASHINGTON – BIO President & CEO John F. Crowley released the following statement on the results of the 2024 U.S. election: “We look forward to working closely with President-elect Trump, his incoming ...

BIO filed an amicus brief in the Supreme Court of the State of California, encouraging its review of the lower court decision in the Gilead Tenofovir Cases. The Court of Appeal decision operates from ...